Sensydia Corp

Sensydia Corporation, based in Los Angeles, US, specializes in non-invasive medical technology, providing advanced hemodynamic measurements to enhance patient care in critical cardiovascular conditions. Founded in 2015 in Los Angeles, Sensydia Corporation focuses on medical technology solutions. The firm has executed a total of 4 deals, with its latest funding round, a Grant, amounting to USD 600,000 from The National Institutes of Health in June 2023. To date, the company has raised a total of USD 7.

80 mn. Aman Mahajan is the founder of Sensydia. Sensydia’s primary offering is the Cardiac Performance System™ (CPS), an automated, non-invasive platform designed to deliver vital hemodynamic measurements with accuracy comparable to traditional gold-standard methods. The CPS was FDA-approved in 2018 and facilitates the rapid assessment of critical metrics such as Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP).

Healthcare providers can easily operate the system through user-friendly, on-screen instructions, making it particularly beneficial for hospitals, including ICUs and ERs, as well as cardiology and medical offices. Sensydia’s products aim to enhance patient care for conditions like heart failure and sepsis, focusing on the North American and European markets where advanced cardiovascular care is a priority. Sensydia generates revenue through the sale of its Cardiac Performance System™ and associated disposable sensors to healthcare institutions and medical offices. This business model involves direct sales to hospitals and clinics, where healthcare providers utilize the CPS for immediate patient assessments.

Transactions typically involve purchasing the CPS platform along with ongoing sensor supplies for each patient evaluation, establishing a steady stream of revenue as clinicians rely on the CPS for acute care and ongoing monitoring. In June 2023, Sensydia Corp raised USD 600,000 in grant funding from The National Institutes of Health, with an additional USD 2. 4 million expected upon the achievement of certain milestones. This funding will support the clinical testing of the Cardiac Performance System (CPS).

The company is focused on expanding its market presence, with plans to introduce new products designed to enhance its CPS technology and penetrate additional geographic markets by 2024.